Mar 21, 2023Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine
SNAP-CAR recognized in research detailing advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility WEXFORD, Pa., March 21, 2023 /PRNewswire
Feb 7, 2023Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling
Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services WEXFORD, Pa., Feb. 7, 2023 /PRNewswire/ -- Coeptis Therapeutics...
Jan 31, 2023Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ -- Coeptis...
Nov 22, 2022
Coeptis to collaborate with IQVIA, a global contract research organization, to identify target indications and initiate IND-enabling activities for SNAP-CAR WEXFORD, Pa., Nov. 22, 2022...
Nov 15, 2022
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that President, Chairman and CEO Dave...